All In Biotech

NDA 215596 · Takeda Pharms USA

Livtencity

Maribavir · Oral · Cytomegalovirus pUL97 Kinase Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Nov 23, 2021: To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 23, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

18

8 Phase 3, 6 recruiting

FAERS reports

2,469

2,128 serious, 536 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 27, 2026.

LIVTENCITY ® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . LIVTENCITY is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. ( 1 , 8.4 )

Mechanism: LIVTENCITY is an antiviral drug against human CMV [see Microbiology (12.4) ] .

Therapeutic areas: Oncology · Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 21, 2025 Supplement 7 · Efficacy OrphanLetterLabel
  • Nov 23, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
  • LIVTENCITY · MARIBAVIR 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Maribavir" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death317
  • dysgeusia268
  • taste disorder229
  • hospitalisation223
  • off label use206
  • cytomegalovirus infection189
  • drug ineffective187
  • drug resistance184
  • fatigue176
  • cytomegalovirus infection reactivation156
  • product use issue136
  • diarrhoea133

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20132
20152
20161
20172
201812
201911
20209
202117
2022497
2023514
2024563
2025556
2026282

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Livtencity (Maribavir)

2024 spending

$52.0M

Beneficiaries

628

2,147 claims

Per beneficiary

$82,778

$215.88 per unit

View as table
YearSpending
2020$0
2021$381,019
2022$20,226,514
2023$37,459,523
2024$51,984,298

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.